Martínez TG, Gómez JA, Sánchez RV, Rodríguez PC, Torres RB, Torres LAM

Language: Spanish
References: 17
Page: 388-396
PDF size: 116.15 Kb.

ABSTRACT

Introduction: rheumatoid arthritis is a chronic inflammatory disease, multisystem and with autoimmune cause. Antibodies anti- citrullinated peptides are an important tool for the diagnosis of this disease.
Objective: to determine the relationship of rheumatoid factor, anti-mutated citrullinated vimentin and anti-citrullinated peptides of second and third generation antibodies, with clinical and serological indicators of disease activity in patients with established rheumatoid arthritis.
Material and methods: 88 patients with established rheumatoid arthritis participated in the study and C reactive protein, erythrocyte sedimentation rate, disease activity score based on the count of 28 joints (DAS 28) and autoantibodies were measured. Rheumatoid factor and anti-citrullinated peptides of second and third generation autoantibodies were quantified by enzyme-linked immunosorbent assay.
Results: association between C reactive protein and the presence of all autoantibodies was observed. Rheumatoid factor and anti-citrullinated peptides antibodies of second and third generation showed positive correlation with ESR and DAS 28. Only anti-citrullinated peptide antibodies were associated with a moderate or high disease activity.
Conclusions: anti-citrullinated peptide antibodies of second and third generation are of great value for identifying patients with more severe disease course in established rheumatoid arthritis.

REFERENCES

1. Abbas AK, Lichtman A, Pillai S. Celular and Molecular Immunology. 7ma ed. Amsterdam: Elseiver; 2012.

2. Kochi Y SA, Yamada R, Yamamoto K. Ethnogenetic heterogeneity of rheumatoid arthritis—implications for pathogenesis. NR Rheum. 2010;6(1):290-95.

3. Arnett FC, Bloch DA. The American Rheumatism association 1987. Revised criteria for the classification of Rheumatoid Arthritis. Arthritis Rheum. 1988;31:315-23.

4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, col. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581.

5. Burr M, Viatte S, Bukhari M, Plant D, Symmons D, Thomson W, col. Long-term stability of anti-cyclic citrullinated peptide antibody status in patients with early inflammatory polyarthritis. Arthritis Research & Therapy. 2012;14:109.

6. Levesque M, Zhou Z, Moreland L. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum. 2009;60:2211-2215.

7. Swart A, Rufus W, Burlingame B, Gürtler I, Mahler M. Third generation anticitrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta. 2012;414:266-272.

8. Díaz-Toscano ML, Olivas-Flores EM, Zavaleta-uñiz SA, Gámez-Nava JI, Cardona- Muñoz EG, Ponce-Guarneros M, col. Comparison of two assays to determine anticitrullinated peptide antibodies in rheumatoid arthritis in relation to other chronic inflammatory rheumatic diseases: assaying anti-modified citrullinated vimentin antibodies adds value to second-generation anti-citrullinated cyclic peptides testing. Biomed Res Int. 2014.

9. Zahran W, Mahmoud M, Shalaby K, Abbas M. Unique Correlation Between Mutated Citrullinated Vimentine IgG Autoantibodies and Markers of Systemic Inammation in Rheumatoid Arthritis Patients. Ind J Clin Biochem. 2013,28(3):272-276.

10. World Medical Association Declaration of Helsinki. Ethical principles for mdical research involving human subjects. WMA: 2013.

11. Demoruelle M, Parish M, Derber L, Kolfenbach J, Hughes-Austin J, Weisman M y col. Anti-cyclic citrullinated peptide assays differ in subjects at elevated risk for rheumatoid arthritis and subjects with established disease. Arthritis Rheum. 2013;65(9):2243-2252.

12. Pruijn G, Wiik A, Venrooij JV. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Research & Therapy. 2010;12:203.

13. González-López L, Rocha-Muñoz AD, Ponce-Guarneros M, Flores-Chávez A, Salazar-Paramo M, Nava A, col. Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis. J Immunol Res. 2014.

14. Henrique da Mota LM, Neto LL, Pereira IA, Burlingame R, Menard H, Laurindo IM. Autoantibodies in early rheumatoid arthritis-Brasília cohort- results of a threeyear serial analysis. Rev Bras Reumatol. 2011;51(6):558-571.

15. Castro C, Gourley M. Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010;125(2):238-47.

16. Kokuina H, Chico A, Carballar L, Gutiérrez A, Soto J, Estévez M, col. Factor reumoideo: Asociación erosión radiológica con la actividad de la artritis reumatoidea. Rev Cub Med. 2008;47(3).

17. Shidara K, Inoue E, Hoshi D, Sato E, Nakajima A, Momohara S, col. Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan. Rheumatol Int. 2012;32(2):361-366.